Moderna announces effectiveness of its Covid-19 vaccine for adolescents

RIO DE JANEIRO, BRAZIL – Moderna Pharmaceuticals announced on May 25 that its Covid-19 vaccine is safe and effective for adolescents between the ages of 12 and 17, making it the second vaccine approved in the U.S. for this age group.

Moderna announced Tuesday that it will submit the results of its clinical study to the U.S. Food and Drug Administration (FDA) in early June for approval of its use with this age group.

The study, carried out on 3,700 adolescents in the United States, reveals the same effectiveness against the disease as among adults, with 93% protection after the second dose.

Regarding side effects, Moderna cited side effects similar to those reported in adults, such as arm pain, fatigue and headaches.

RNA-1273 (the vaccine’s technical name) has been shown to be “highly effective in preventing Covid-19 in adolescents,” Stéphane Bancel, Moderna’s CEO, stated in a press release.

If approved, it would be the second vaccine available in the U.S. for adolescents, after regulatory authorities approved the use of the Pfizer/BioNTech’s vaccine on May 10.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error